Dyadic Narrows Losses, Rebrands Amid Strategic Shift to Non-Therapeutic Proteins

TL;DR

**DYAI is burning cash fast, but new grants and a strategic pivot to non-therapeutic proteins could be a lifeline if they execute quickly.**

AI Summary

DYADIC INTERNATIONAL INC reported a net loss of $1,793,774 for the three months ended June 30, 2025, an improvement from a net loss of $2,045,223 in the prior-year period. For the six months ended June 30, 2025, the net loss was $3,821,353, compared to $4,054,819 for the same period in 2024. Total revenue significantly increased to $966,630 for the three months ended June 30, 2025, up from $385,896 in 2024, driven by $503,181 in grant revenue and $250,000 in license and milestone revenue, which were zero in the prior year. Research and development revenue, however, decreased from $385,896 to $213,449. Cash and cash equivalents decreased substantially from $6,506,750 at December 31, 2024, to $2,140,899 at June 30, 2025. The company also rebranded to Dyadic Applied BioSolutions on August 1, 2025, signaling a strategic shift towards commercializing non-therapeutic proteins. Key risks include a history of net losses and dependence on third-party collaborations and capital raising to fund its C1 and Dapibus platforms.

Why It Matters

This filing reveals Dyadic's strategic pivot towards non-therapeutic proteins, a move that could accelerate time to revenue and broaden market reach by avoiding complex regulatory hurdles and high costs associated with therapeutic biologics. For investors, the significant increase in grant and license revenue, including a $3,092,136 grant from the Gates Foundation and a $4.5 million grant from CEPI, indicates external validation and funding for its C1 platform, potentially de-risking some development costs. However, the substantial decline in cash and cash equivalents, from $6.5 million to $2.1 million, highlights ongoing liquidity challenges and the critical need for successful commercialization or further capital raises to sustain operations and compete effectively in the biotechnology sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $3,821,353 for the six months ended June 30, 2025, and explicitly states it expects to incur further losses and negative net cash flows from operating activities. Cash and cash equivalents plummeted from $6,506,750 at December 31, 2024, to $2,140,899 at June 30, 2025, indicating a rapid cash burn rate. This raises substantial doubt about the Company's ability to continue as a going concern, as noted in the filing.

Analyst Insight

Investors should closely monitor Dyadic's progress in commercializing its C1 and Dapibus platforms and securing additional funding. While the new grants are positive, the rapid cash burn and history of losses necessitate caution. Consider this a speculative investment, contingent on successful execution of its strategic shift and effective capital management.

Financial Highlights

debt To Equity

N/A

revenue

$966,630

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,793,774

eps

N/A

gross Margin

N/A

cash Position

$2,140,899

revenue Growth

+150.5%

Revenue Breakdown

Key Numbers

• $1,793,774 — Net loss for Q2 2025 (Improved from $2,045,223 in Q2 2024)
• $3,821,353 — Net loss for H1 2025 (Improved from $4,054,819 in H1 2024)
• $966,630 — Total revenue for Q2 2025 (Increased from $385,896 in Q2 2024)
• $503,181 — Grant revenue for Q2 2025 (New revenue stream, zero in Q2 2024)
• $250,000 — License and milestone revenue for Q2 2025 (New revenue stream, zero in Q2 2024)
• $2,140,899 — Cash and cash equivalents at June 30, 2025 (Decreased from $6,506,750 at December 31, 2024)
• $3,092,136 — Gates Foundation Grant (Awarded November 16, 2024, for C1 platform development)
• $4.5 million — CEPI Grant (Awarded March 20, 2025, for C1 platform vaccine development)
• $6.0 million — Aggregate principal amount of Convertible Notes (Issued March 8, 2024, with 8.0% interest)
• 36,187,798 — Common Stock shares outstanding (As of August 12, 2025)

Key Players & Entities

• DYADIC INTERNATIONAL INC (company) — registrant
• Mark Emalfarb (person) — President and Chief Executive Officer
• Gates Foundation (company) — grant provider for $3,092,136
• CEPI (company) — grant provider for $4.5 million
• Fondazione Biotecnopolo di Siena (company) — intermediary for CEPI grant
• The Francisco Trust (company) — existing holder of more than 5% of common stock and purchaser of convertible notes
• NASDAQ Stock Market LLC (regulator) — exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• History of Net Losses [high — financial]: The company has a history of significant net losses, including $1,793,774 for Q2 2025 and $3,821,353 for H1 2025. This ongoing unprofitability raises concerns about financial sustainability.
• Dependence on Capital Raising [high — financial]: Dyadic International relies on external capital raising to fund its operations and platform development. This dependence creates risk if future financing cannot be secured on favorable terms.
• Reliance on Third-Party Collaborations [medium — operational]: The company's success is tied to its C1 and Dapibus platforms, which depend on third-party collaborations. Disruptions or failures in these collaborations could significantly impact the business.
• Cash Burn Rate [high — financial]: Cash and cash equivalents decreased from $6,506,750 at December 31, 2024, to $2,140,899 at June 30, 2025, indicating a substantial burn rate that requires careful management and future funding.

Industry Context

Dyadic International operates in the biotechnology sector, focusing on protein production platforms. The industry is characterized by significant R&D investment, reliance on intellectual property, and the need for strategic partnerships to bring products to market. Trends include the increasing demand for efficient and scalable biomanufacturing solutions for both therapeutic and non-therapeutic applications.

Regulatory Implications

As a biotechnology company, Dyadic is subject to regulatory oversight, particularly concerning the development and commercialization of its protein products. While the current focus on non-therapeutic proteins may reduce direct FDA scrutiny compared to therapeutics, compliance with manufacturing standards and intellectual property laws remains critical.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Evaluate the success of the strategic shift to non-therapeutic proteins.
3. Assess the impact of new revenue streams (grants, licenses).

Key Dates

• 2025-08-01: Rebranded to Dyadic Applied BioSolutions — Signals a strategic shift towards commercializing non-therapeutic proteins, indicating a potential change in business focus and market strategy.
• 2025-03-20: Awarded CEPI Grant — Received a $4.5 million grant for C1 platform vaccine development, validating the platform's potential and providing non-dilutive funding.
• 2024-11-16: Awarded Gates Foundation Grant — Secured a $3,092,136 grant for C1 platform development, demonstrating external confidence in the technology and providing crucial funding.
• 2024-03-08: Issued Convertible Notes — Issued $6.0 million in convertible notes with 8.0% interest, providing capital but also introducing debt obligations and potential future dilution.

Glossary

C1 Platform

A proprietary microbial gene expression platform developed by Dyadic International, designed for the efficient production of proteins. (Central to the company's technology and revenue generation through licensing and collaborations.)

Dapibus Platform

Another proprietary platform from Dyadic International, likely focused on specific applications or protein types. (A key asset that the company aims to commercialize, contributing to its strategic direction.)

Grant Revenue

Revenue recognized from grants awarded to the company, often for research and development purposes, which do not require repayment. (A significant new source of income for Dyadic in Q2 2025, helping to offset operating losses.)

License and Milestone Revenue

Revenue earned from granting licenses for the use of its technology and from achieving specific milestones in collaborative agreements. (A key component of Dyadic's commercialization strategy, contributing to revenue growth.)

Convertible Notes

Debt instruments that can be converted into shares of the issuing company's stock under certain conditions. (Represents a source of funding for Dyadic, but carries the risk of future equity dilution.)

Year-Over-Year Comparison

Dyadic International has shown a notable improvement in revenue for the three months ended June 30, 2025, increasing to $966,630 from $385,896 in the prior year, largely due to new grant and license revenue streams. While the net loss has narrowed slightly to $1,793,774 from $2,045,223, the company's cash position has significantly declined from $6,506,750 to $2,140,899, underscoring continued operational expenses and reliance on external funding. New risks related to the commercialization strategy are emerging alongside the positive revenue developments.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share DYAI The NASDAQ Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 1068KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• form10-q_001.jpg (GRAPHIC) — 19KB
• 0001641172-25-023492.txt ( ) — 6440KB
• dyai-20250630.xsd (EX-101.SCH) — 40KB
• dyai-20250630_cal.xml (EX-101.CAL) — 50KB
• dyai-20250630_def.xml (EX-101.DEF) — 234KB
• dyai-20250630_lab.xml (EX-101.LAB) — 420KB
• dyai-20250630_pre.xml (EX-101.PRE) — 335KB
• form10-q_htm.xml (XML) — 1054KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30

OTHER INFORMATION

PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32

Signatures

Signatures 33 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of the federal securities laws, particularly under Item 2 "Management's Discussion and Analysis." All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding industry prospects, future business, future results of operations or financial condition, future liquidity and capital resources, our ability to implement our agreements with third parties, management strategies, and our competitive position. Forward-looking statements generally can be identified by use of the words "expect," "should," "intend," "anticipate," "will," "project," "may," "might," "potential," or "continue" and other similar terms or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking to (i) our history of net losses (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies (iii) failure to commercialize our microbial protein production platforms or our other technologies (iv) competition, including from alternative technologies (v) the results of nonclinical studies and clinical trials (vi) our capital needs (vii) changes in global economic and financial conditions (viii) our reliance on information technology (ix) our dependence on thi

View Full Filing

View this 10-Q filing on SEC EDGAR